Research Article

Interferon-Gamma Inducible Protein-10: Not a Mortality Marker for COVID-19 Disease

Volume: 8 Number: 3 September 6, 2023
EN TR

Interferon-Gamma Inducible Protein-10: Not a Mortality Marker for COVID-19 Disease

Abstract

Objective: Interferon-gamma inducible protein-10 (IP-10) released from macrophages is associated with thrombosis. We aimed to investigate patients' biochemical markers following severe COVID-19, concentrating on the role of IP-10 in mortality. Materials and Methods: In our study, we retrospectively evaluated data from 88 (females, 44.3%) severe patients followed in our university hospital's intensive care unit (ICU). We obtained demographic and laboratory data from our study population's files and electronic records, including D-dimer, ferritin, uric acid, IP-10 values, and other biochemical markers. Results: The mean age of all 88 patients with COVID-19 infection followed in the ICU was 70.5 ±10 years. The median for lymphocyte count was 1.3 (1-2.1) vs 0.8 (0.5-1.1) K/uL, ferritin 151 (90.7-255) vs 624 (296-1254) mcg/L, D-dimer 386 (293.5-650) vs 1280 (871-2245) ug/L, LDH 220 (185-286) vs 429.5 (368-560) U/L with a p-value of <0.05 in survivors vs non-survivors respectively. On the other hand, the level of IP-10 was 21.3 (13.2-31.6) vs 26.6 (11.4-43.6) pg/mL with a p-value of 0.04. Conclusions: In this study, in which non-survivors and survivors were compared in severe COVID-19 patients, it was found that ferritin and D-dimer were good predictors of mortality, while IP-10 could not be a predictor of mortality.

Keywords

Supporting Institution

Sakarya University of Scientific Research Projects Unit

Project Number

BAPK 2021-9-33-83

Thanks

We want to thank the Sakarya University of Scientific Research Projects Unit (Research Project number: BAPK 2021-9-33-83) for their financial support. Also, we would like to thank the company HUMANİS for their contribution and nonconditional support.

References

  1. Chen Y, Wang J, Liu C, Su L, Zhang D, Fan J, et al. IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19. Mol Med. 2020;26(1):97. doi:10.1186/s10020-020-00230-x
  2. Clinical spectrum. COVID-19 Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/. Accessed May 19, 2023.
  3. Corominas H, Castellví I, Pomar V, Antonijoan R, Mur I, Matas L, et al. Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort. Clin Immunol. 2021;223:108631. doi:10.1016/j.clim.2020.108631
  4. Buszko M, Park JH, Verthelyi D, Sen R, Young HA, Rosenberg AS. The dynamic changes in cytokine responses in COVID-19: a snapshot of the current state of knowledge. Nat Immunol. 2020;21(10):1146-1151. doi:10.1038/s41590-020-0779-1
  5. Schultze JL, Aschenbrenner AC. COVID-19 and the human innate immune system. Cell. 2021;184(7):1671-1692. doi:10.1016/j.cell.2021.02.029
  6. Bignon E, Miclot T, Terenzi A, Barone G, Monari A. Structure of the 5’ untranslated region in SARS-CoV-2 genome and its specific recognition by innate immune system via the human oligoadenylate synthase 1. Chem Commun . 2022;58(13):2176-2179. doi:10.1039/d1cc07006a
  7. Lu Q, Zhu Z, Tan C, Zhou H, Hu Y, Shen G, et al. Changes of serum IL-10, IL-1β, IL-6, MCP-1, TNF-α, IP-10 and IL-4 in COVID-19 patients. Int J Clin Pract. 2021;75(9):e14462. doi:10.1111/ijcp.14462
  8. Sriram K, Insel PA. Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets. Physiol Rev. 2021;101(2):545-567. doi:10.1152/physrev.00035.2020

Details

Primary Language

English

Subjects

Medical Infection Agents

Journal Section

Research Article

Early Pub Date

August 30, 2023

Publication Date

September 6, 2023

Submission Date

April 4, 2023

Acceptance Date

July 15, 2023

Published in Issue

Year 2023 Volume: 8 Number: 3

AMA
1.İslam M, Dheir H, Özözen Şahin E, et al. Interferon-Gamma Inducible Protein-10: Not a Mortality Marker for COVID-19 Disease. OTJHS. 2023;8(3):363-368. doi:10.26453/otjhs.1276809

Creative Commons License
 

Online Türk Sağlık Bilimleri Dergisi [Online Turkish Journal of Health Sciences (OTJHS)] is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This is an open-access journal distributed under the terms of the Creative Commons Attribution License (CC BY-NC 4.0). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Click here to get help about article submission processes and "Copyright Transfer Form".